Allergan Reports Product Net Sales Of $1.11b

Allergan reported $0.58 diluted earnings per share attributable to stockholders compared to $0.47 diluted earnings per share attributable to stockholders reported for the second quarter of 2008.

Allergan’s non-GAAP diluted earnings per share attributable to stockholders were $0.75 in the second quarter of 2009, compared to non-GAAP diluted earnings per share attributable to stockholders of $0.63 in the second quarter of 2008, a 19.0% year-over-year increase.

Allergan’s total product net sales were $1,118.7m. Total product net sales decreased 3.2% as compared to total product net sales in the second quarter of 2008.

David Pyott, chairman and chief executive officer, Allergan, said: Our balanced portfolio of products, the contribution from recently launched products, disciplined execution of our operating plans and management’s attention to cost have all contributed to strong financial performance in the second quarter. Furthermore, we are excited by the recent FDA approval of OZURDEX (dexamethasone intravitreal implant) 0.7mg and look forward to entering the rapidly growing retina market with the first FDA-approved drug treatment for macular edema following retinal vein occlusion.